Now, this won't come as too much of a surprise to Eli Lilly and its peers. A few weeks ago, the company's CEO, David Ricks, ...

This time next year, you may be swapping your GLP-1 injections for easier and as-effective oral weight-loss medication. It's ...

We came across a bullish thesis on Eli Lilly and Company ... These two drugs alone are transforming Lilly’s growth profile and have propelled the company to a leadership position alongside ...

Ricks said reshoring manufacturing capacity for older essential medicines is “a valid thing,” adding that Eli Lilly is “happy ...

Eli Lilly said sales of weight loss drug Zepbound and diabetes treatment Mounjaro surged in the first quarter.

Eli Lilly and Purdue University expand their partnership with a $250 million investment to advance pharmaceutical innovation ...

Eli Lilly launched a couple of new successful drugs, Mounjaro and Zepbound, that have boosted its market value. The company's revenue and profits are expected to double in 2025 due to strong sales ...

CEO David Joyner tells Yahoo Finance he's working to define the company. President Trump ... which suggests that Eli Lilly’s... GLP-1 drug prices are falling. That's good news for patients ...

The head of drugmaker Eli Lilly, which sells the popular weight-loss drug Zepbound, urged the Trump administration to ease up on its [tariff rollout]( ...

Eli Lilly on Thursday ... a certain oral cancer drug from Scorpion Therapeutics. The company maintained its fiscal 2025 sales guidance of $58 billion to $61 billion. Eli Lilly said the guidance ...

Eli Lilly on Thursday ... oral cancer drug from Scorpion Therapeutics. Get top local stories delivered to you every morning with NBC DFW's News Headlines newsletter. The company maintained its ...